Tirzepatide mitigates cognitive decline in zebrafish model of type 2 diabetes mellitus induced by high-fat diet
- PMID: 39873719
- DOI: 10.1007/s00210-025-03827-3
Tirzepatide mitigates cognitive decline in zebrafish model of type 2 diabetes mellitus induced by high-fat diet
Abstract
In examining the enduring consequences of diabetes, recent research has focused on the anticipated outcomes of the condition. Specifically, cognitive impairment has been linked to diabetes mellitus dating back to the discovery of insulin. This study delves into the neuroprotective effects of TZP, i.e. tirzepatide a dual GIP and GLP-1 receptor agonist that works by mimicking these two gut hormones, against cognitive impairment associated with type 2 diabetes mellitus (T2DM). T2DM-like zebrafish model of varying age groups was created through a 6-week administration of a high-fat diet (HFD). Parameters such as body weight, body mass index, and blood glucose levels were monitored, and behavioural assessments (T-maze, novel tank diving test, and inhibitory avoidance test) were conducted at the conclusion of the protocol to assess learning and memory. Additionally, lipid profile biochemical parameters (MDA, AChEs, and GSH), molecular markers (IL-1β, IL-10, TNF-α, Bcl-2, Bax, GSK-3β, and AMPK), and histopathological examinations were performed. Treatment with the novel GLP-1 and GIP dual agonist TZP (10 nM/kg, i.p.) significantly ameliorated cognitive impairment, as evidenced by behavioural parameters, and restored antioxidant like GSH (p < 0.05) and catalase (p < 0.05) and anti-inflammatory marker levels, i.e. IL-10 (p < 0.05) compared to the HFD group. TZP also mitigated abnormal glucose (73.2 ± 5.889) and lipid profiles (TG 0.159 ± 0.0075 and TC 0.100 ± 0.0020) in hyperglycaemic zebrafish. This study suggests that the positive effects of TZP on cognition and memory may stem from its neuroprotective capabilities, potentially attributed to its antioxidant, anti-inflammatory, and anti-apoptotic properties, as well as its ability to enhance AMPK levels as GLP-1 agonist has the potential to increase the level of AMPK.
Keywords: Cognitive impairment; Diabetes mellitus; Neurodegeneration; Tirzepatide; Zebrafish.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Similar articles
-
Comparative Analysis of Pioglitazone and Tirzepatide on Body Weight, Glucose Levels, Neuroinflammation, and Oxidative Stress in Diabetic Rats.Drug Des Devel Ther. 2025 Jul 31;19:6605-6618. doi: 10.2147/DDDT.S525690. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40771859 Free PMC article.
-
Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.EBioMedicine. 2025 Jul;117:105791. doi: 10.1016/j.ebiom.2025.105791. Epub 2025 Jun 6. EBioMedicine. 2025. PMID: 40479843 Free PMC article.
-
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.Diabetes Obes Metab. 2024 Dec;26(12):5982-5994. doi: 10.1111/dom.15972. Epub 2024 Sep 30. Diabetes Obes Metab. 2024. PMID: 39344853
-
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17. Diabetologia. 2022. PMID: 35579691 Free PMC article.
-
Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.Clin Ther. 2023 Aug;45(8):787-796. doi: 10.1016/j.clinthera.2023.06.008. Epub 2023 Jul 14. Clin Ther. 2023. PMID: 37455226
References
-
- Abdel-Mageed HM, Abd El Aziz AE, Abdel Raouf BM, Mohamed SA, Nada D (2022) Antioxidant-biocompatible and stable catalase-based gelatin–alginate hydrogel scaffold with thermal wound healing capability: immobilization and delivery approach. 3 Biotech 12(3):73
-
- Agrawal M, Singhal M, Semwal BC, Arora S, Singh B, Sikarwar V, . . . Bhargva S (2024) Neuroprotective action of hordenine against the aluminium chloride (AlCl3) induced Alzheimer's diseases & associated memory impairment in experimental rats. Pharmacol Res-Mod Chin Med 12:100492
-
- Al Shoyaib A, Archie SR, Karamyan VT (2020) Intraperitoneal route of drug administration: should it be used in experimental animal studies? Pharm Res 37:1–17
-
- Andrés CMC, Pérez de la Lastra JM, Juan CA, Plou FJ, Pérez-Lebeña E (2022) Chemistry of hydrogen peroxide formation and elimination in mammalian cells, and its role in various pathologies. Stresses 2(3):256–274
-
- Asimaki A, Kapoor S, Plovie E, Karin Arndt A, Adams E, Liu Z, . . . Churko J (2014) Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. Sci Trans Med 6(240):240ra274–240ra274
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous